Treatment of autosomal recessive and autosomal dominant polycystic kidney disease
https://doi.org/10.21508/1027-4065-2019-64-2-22-29
Abstract
The article reflects the genetic variants of polycystic kidney disease, describes the modern strategy for the treatment of polycystic kidney disease in children and adults. The authors present the results of clinical trials of vasopressin V2 receptor antagonists (tolvaptan, liksivaptan), a multi-kinase inhibitor (tezevatinib), somatostatin analogues (lankreotide, octreotide), statins (pravastatin), mTOR inhibitors (everolimus, sirolimus), metformin in patients with autosomal recessive and autosomal polycystic kidney disease. The authors discuss the factors determining the prognosis and outcome of these diseases.
About the Authors
E. F. Andreeva
Saint-Petersburg State Pediatric Medical University
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
N. D. Savenkova
Saint-Petersburg State Pediatric Medical University
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Ignatova M.S., Dlin V.V. Role of genetics in the development of pediatric nephrology. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2015; 60(3): 6–9. (in Russ)
2. Nikolaeva E.A., Semyachkina A.N. Modern possibilities of hereditary diseases treatment in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2018; 63(4): 6–14. (in Russ) DOI: 10.21508/1027-4065-2018-63-4-6-14
3. Bergmann C. Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front Pediatr 2018; 5:221–234. DOI: 10.3389/fped.2017.00221
4. Bergmann C., Guay-Woodford L.M., Harris P.C., Horie S., Peters D.J. M., Torres V.E. Polycystic kidney disease. Nature Reviews Disease Primers 2018; 4(1): 50–74. DOI: 10.1038/s41572-018-0047-y
5. Aymé S., Bauerenhauer D., Day S., Devuyst O., Guay-Woodford L. M., Ingelfinger J.R. et al. Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Intern 2017; 92(4): 796–808. DOI: 10.1016/j.kint.2017.06.018
6. The National Library of Medicine (NLM). ClinicalTrials.gov. https://clinicaltrials.gov (ссылка активна на 20.12.2018).
7. Polycystic Kidney Disease foundation. ttps://pkdcure.org. Ссылка активна на 20.12.2018.
8. Patil A., Sweeney Jr. W.E., Avner E.D., Pan C. Childhood Polycystic Kidney Disease. In: X. Li (ed.). Polycystic Kidney Disease. Codon Publications, Brisbane, Australia, 2015; 21–60. DOI: 10.15586/codon.pkd.2015
9. Harutyunyan S., Andreeva E., Savenkova N., Larionova V., Leviashvili G. Extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Pediatr Nephrol 2011; 26(9): 1691.
10. Bonsib S.M. The Classification of Renal Cystic Diseases and Other Congenital Malformations of the Kidney and Urinary Tract. Arch Pathol Lab Med 2010; 134 (4): 554–567. DOI: 10.1043/1543-2165-134.4.554
11. Andreeva E.F., Savenkova N.D. Cystic kidney disease in children (literature review). Nephrology 2012; 16 (3/2): 34–47. (in Russ) DOI: 10.24884/1561-6274-2012-16-3/2-34-47
12. Andreeva E.F. The follow-up of children and adolescents with polycystic kidney disease. Nephrology 2016; 20(3): 60–68. (in Russ)
13. Online Mendelian Inheritance in Man. http://omim.org (ссылка активна на 20.12.2018).
14. Andreeva E.F., Savenkova N.D., Tilouche M.A., Natochina N.Y., Dug I.V. Features of the course of autosomal recessive polycystic kidney disease in children. Pediatr 2016; 7(4): 45–49. (in Russ)
15. Lu H., Galeano M.C.R., Ott E., Kaeslin G., Kausalya P.J., Kramer C. et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nature Genet 2017; 49(7): 1025–1034. DOI: 10.1038/ng.3871
16. Arutyunyan S.S., Savenkova N.D. Characteristics of renal and extrarenal manifestations of autosomal dominant polycystic kidney disease in children. Nephrology 2013; 17(3): 60–67. (in Russ) DOI: 10.24884/1561-6274-2013-17-3-60-67
17. Sweeney Jr.W.E., Gunay-Aygun M., Patil A., Avner E.D. Childhood Polycystic Kidney Disease In: E.D. Avner, W.E. Harmon, P. Niaudet, N. Yoshikawa, F. Emma, S.L. Goldstein (eds). Pediatric Nephrology, 7nd ed. Springer-Verlag, Berlin Heidelberg, 2016; 1103–1153. DOI: 10.1007/978-3-662-43596-0
18. Polycystic Kidney Disease Outcomes Consortium. Qualification of Total Kidney Volume as a Prognostic Biomarker for use in Clinical Trials Evaluating Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Final Briefing Book, 2014. http://www.ema.europa.eu. Ссылка активна на 20.12.2018.
19. Riella С., Czarnecki P.G., Steinman T.I. Therapeutic Advances in the Treatment of Polycystic Kidney Disease. Nephron Clin Pract 2014; 128: 297–302. DOI: 10.1159/000368244
20. Xue C., Zhou C.-C., Wu M., Mei C.-L. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. Kidney Dis 2016; 2(3): 111–119. DOI: 10.1159/000449030
21. Reddy B.V., Chapman A.B. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol 2016; 32(1): 31–42. DOI: 10.1007/s00467-016-3364-y
22. Savenkova N.D. Renal Arterial Hypertension in children and adolescents: causes, classification, diagnosis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2017; 62(4): 43–48. (in Russ) DOI: 10.21508/1027–4065–2017–62–4–43–48
23. Sweeney Jr.W.E., Avner E.D. Emerging Therapies for Childhood Polycystic Kidney Disease. Front Pediatr 2017; 5: 77. DOI: 10.3389/fped.2017.00077
24. Mangolini A., Stephanis L., Aguiari G. Role of calcium in polycystic kidney disease: From signaling to pathology. World J Nephrol 2016; 5(1): 76–83. DOI: 10.5527/wjn.v5.i1.76
25. Papizh S.V., Dlin V.V., Vinogradova T.V., Leont`eva I.V., Tutel`man K.M., Fomin D.K. et al. The role of profibrogenic cytokines in the progression of renal and cardiovascular damage in children with autosomal dominant polycystic kidney disease. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2014; 59(3): 91–98. (in Russ)
26. Network for Early Onset Cystic Kidney Diseases-A Comprehensive Multidisciplinary Approach to Hereditary Cystic Kidney Diseases in Childhood. Network for Early Onset Cystic Kidney Diseases-A Comprehensive Multidisciplinary Approach to Hereditary Cystic Kidney Diseases in Childhood. Front Pediatr 2018; 6: 24. DOI: 10.3389/fped.2018.00024
27. Gimpel C., Avni F.E., Bergmann C., Cetiner M., Habbig S., Haffner D. et al. Perinatal diagnosis, management, and follow-up of cystic renal diseases. JAMA Pediatr 2018; 172(1): 74–86. DOI: 10.1001/jamapediatrics.2017.3938
28. Ebner K., Schaefer F., Liebau M.Ch., the ARegPKD Consortium. Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease. Front Pediatr 2017; 5: 18–23. DOI: 10.3389/fped.2017.00018
29. Ignatova M.S., Kirilina S.A., Dlin V.V. Agapov E.G., Nizhegorodceva T.V. A method of treating children with polycystic kidney disease. Patent search in Russia: new patents, patent applications library patents for inventions. (in Russ) http://www.freepatent.ru/patents/2316322. (Ссылка активна на 20.12.2018).
30. Padovano V., Podrini C., Boletta A., Caplan M.J. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 2018; 14(11): 678–687. DOI: 10.1038/s41581-018-0051-1
31. Janssens P., Weydert C., De Rechter S., Wissing K.M., Liebau M.C., Mekahli D. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Pediatr Nephrol 2018; 33(3): 395–408. DOI: 10.1007/s00467-017-3672-x
32. Casteleijn N.F., Blais J.D., Chapman A.B., Czerwiec F.S., Devuyst O., Higashihara E. et al. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis 2017; 69(2): 210–219. DOI: 10.1053/j.ajkd.2016.08.028
33. Morimoto K., Akai Y., Matsui M., Yano H., Tagawa M., Samejima K. et al. Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomaldominant polycystic kidney disease. CEN Case Reports 2017; 6(1): 61–65. DOI: 10.1007/s13730-016-0245-y
34. Irazabal M.V., Rangel L.J., Bergstralh E.J., Osborn S.L., Harmon A.J., Sundsbak J. L. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2014; 26(1): 160–172. DOI: 10.1681/asn.2013101138
35. Gansevoort R.T., Arici M., Benzing T., Birn H., Capasso G., Covic A. еt al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant 2016; 31: 337–348. DOI: 10.1093/ndt/gfv456
36. Gevers T.J.G., Hol J.C., Monshouwer R., Dekker H.M., Wetzels J.F.M., Drenth J.P.H. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int 2014; 35(5): 1607–1614. DOI: 10.1111/liv.12726
37. Hogan M.C., Masyuk T.V., Page L.J., Kubly V.J., Bergstralh E.J., Li X. et al. Randomized Clinical Trial of LongActing Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. J Am Soc Nephrol 2010; 21(6): 1052–1061. DOI: 10.1681/asn.2009121291
38. Pisani A., Sabbatini M., Imbriaco M., Riccio E., Rubis N., Prinster A. et al. Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 2016; 14(7): 1022–1030. DOI: 10.1016/j.cgh.2015.12.049
39. Guay-Woodford L.M., Bissler J.J., Braun M.C., Bockenhauer D., Cadnapaphornchai M.A., Dell K.M. et al. Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference. J Pediatr 2014; 165(3): 611–617. DOI: 10.1016/j.jpeds.2014.06.015
40. Deep A., Saxena R., Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol 2019; 34: 45–59. DOI: 10.1007/s00467-018-3893-7
41. Bockenhauer D. Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics? Pediatr Nephrol 2017; 32: 721–723. DOI: 10.1007/s00467-017-3578-7
42. Abeuova B.A., Nigmatullina N.B., Alty`nova V.X., Axmad`yar N.S. Clinical diagnosis and treatment protocol. Cystic kidney disease in children. Ministry of Health of the Republic of Kazakhstan, protocol № 10 dated July 4, 2014. (in Russ) https://docplayer.ru/36612925-Klinicheskiy-protokol-diagnostiki-ilecheniya-kistoznaya-bolezn-pochek-u-detey. (Ссылка активна на 20.12.2018).
43. Grenda R., Kaliciński P. Combined and sequential liver–kidney transplantation in children. Pediatr Nephrol 2018; 33(12): 2227–2237. DOI: 10.1007/s00467-017-3880-4
44. Gilbert R.D., Evans H., Olalekan K. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatr Nephrol 2017; 32: 893–896. DOI: 10.1007/s00467-017-3584-9
45. Cadnapaphornchai M.A., George D.M., McFann K., Wang W., Gitomer B., Strain J.D. et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2014; 9(5): 889–896. DOI: 10.2215/cjn.08350813
Review
For citations:
Andreeva E.F., Savenkova N.D. Treatment of autosomal recessive and autosomal dominant polycystic kidney disease. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2019;64(2):22-29. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-2-22-29
Views:
2306
Email this article 